David Orlando Acero-Garcés

David Orlando Acero-Garcés

Auto-generated profile, based on publicly available information

David Orlando Acero-Garcés

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2023 in Colombia Medica
Verified
Journal Article
Open access
PDF file
DADavid O. Acero-Garcés
David O. Acero-Garcés
WGWilmar Saldarriaga Gil
Wilmar Saldarriaga Gil
AHAna Maria Cabal Herrera
Ana Maria Cabal Herrera
CRChristian A. Rojas
Christian A. Rojas
RHRandi Hagerman
Randi Hagerman
Fragile X syndrome is caused by the expansion of CGG triplets in the FMR1 gene, which generates epigenetic changes that silence its expression. The absence of the protein coded by this gene, FMRP, causes cellular dysfunction, leading to impaired brain development and functional abnormalities. The physical and neurologic manifestations of the disease appear early in life and may suggest the diagnosis. However, it must be confirmed by molecular tests. It affects multiple areas of daily living and greatly burdens the affected individuals and their families. Fragile X syndrome is the most common monogenic cause of intellectual disability and autism spectrum disorder; the diagnosis should be suspected in every patient with neurodevelopmental delay. Early interventions could improve the functional prognosis of patients with Fragile X syndrome, significantly impacting their quality of life and daily functioning. Therefore, healthcare for children with Fragile X syndrome should include a multidisciplinary approach.

9 April 2020 in Current Pediatric Reviews
Verified
Journal Article
Open access
PDF file
DADavid Orlando Acero-Garcés
David Orlando Acero-Garcés
HGHerney Andrés García-Perdomo
Herney Andrés García-Perdomo
Background: The first-line interventions in immune thrombocytopenia (ITP) include intravenous polyclonal immunoglobulins (IVIg), corticosteroids and anti-D immunoglobulin (anti-D). Objective: We aimed to compare the effectiveness and safety of first line treatments for newlydiagnosed primary ITP in children to increase the platelet count. Methods: We searched MEDLINE, EMBASE, LILACS and the Cochrane Central register of Controlled Trials (CENTRAL); and included the clinical trials. We performed the statistical analysis in R. Results: We included 12 studies for meta-analysis. Compared with IVIG 2g/kg, response rates were lower for prednisone 2mg/kg at 72 hours [RR 0.04 (95% CI 0.0 to 0.68)] and at 7 days [RR 0.23 (95% CI 0.08 to 0.67)]; at 48 hours, methylprednisolone 30mg/kg also showed lower response rates [RR 0.72 (95% CI 0.52 to 0.99)]. IVIG 2g/kg and 2.5g/kg had less adverse effects than Anti- D, methylprednisolone and IVIG 0.8g/kg. For rising platelet count, no statistical differences were found at 24 hours or in 7 days; at 48 hours, IVIG 2g/kg showed better results than Anti-D 75μg/kg [MD -58.84 (95% CI -87.02 to -25.66)]. After a month, platelet count with IVIG 2g/kg was higher than Anti-D 50 and 75μg/kg [-82.03 (95% CI -102.60 to -61.46) and -78.77 (95% CI -97.80 to - 59.74), respectively], but lower than methylprednisolone 50mg/kg [MD 118 (95% CI 3.88 to 232.12)]. Conclusion: The total platelet count rises higher in early and late phases with IVIG than Anti-D, but in long term it is higher with methylprednisolone. Additionally, IVIG causes less adverse effects than Anti-D and corticosteroids.

8 November 2026 in Neurology Clinical Practice
Verified
Journal Article
Closed access
PDF file
DADavid O. Acero-Garces
David O. Acero-Garces
EGEliza Gordon-Lipkin
Eliza Gordon-Lipkin
DLDoris Lin
Doris Lin
LSLisa R. Sun
Lisa R. Sun
RFRyan J. Felling
Ryan J. Felling
HCHaiwen Chen
Haiwen Chen
Background and ObjectivesSpinal cord stroke (SCS) is an underrecognized cause of severe acute myelopathy in children that can be misdiagnosed as an infectious or inflammatory process. Limited chara...

21 October 2026 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
AFAngeliki Filippatou
Angeliki Filippatou
SDSusana Dominguez‐Penuela
Susana Dominguez‐Penuela
DADavid Acero‐Garces
David Acero‐Garces
GGGeorgios Gakis
Georgios Gakis
MSMatthew D. Smith
Matthew D. Smith
ESElias S. Sotirchos
Elias S. Sotirchos
Objective: Aquaporin‐4‐IgG seropositive neuromyelitis optica spectrum disorder (AQP4+ NMOSD), myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD), and multiple sclerosis (MS) are pathophysiologically distinct neuroinflammatory disorders. Complement activation is a major mechanism of injury in AQP4+ NMOSD, whereas its role in MS is complex and in MOGAD controversial. We aimed to compare complement components and cytokines between AQP4+ NMOSD, MOGAD, and MS. Methods: CSF complement components, CSF and plasma cytokines, neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) were measured in people with AQP4+ NMOSD (CSF: n = 19; plasma: n = 18), MOGAD (CSF: n = 29; plasma: n = 35) and MS (CSF: n = 36; plasma: n = 58) with recent disease activity. Controls included subjects with non‐inflammatory conditions (CSF: n = 51) and healthy controls (plasma: n = 29). Results: CSF IL‐10 and TNF‐a were elevated across all neuroinflammatory disease groups relative to controls. CSF IL‐6 was elevated only in AQP4+ NMOSD and MOGAD. There were no significant differences in plasma cytokines between groups. Most complement components were elevated in AQP4+ NMOSD and MOGAD; only specific activation products (C2b, C3d, C4a, C5a) were elevated in MS. CSF GFAP and NfL correlated with several CSF cytokines and complement components in AQP4+ NMOSD and MOGAD. Expanded Disability Status Scale at nadir during attacks correlated with CSF BAFF, GFAP, free C1q, C1s, C1s‐C1inh, C4a in AQP4+ NMOSD, and CSF IL‐10, TNF‐a, free C1q, C1inh, C4a in MOGAD. Interpretation: Our findings suggest distinct CSF cytokine profiles in AQP4+ NMOSD, MOGAD, and MS, and widespread activation of complement pathways in AQP4+ NMOSD and MOGAD. CSF complement and cytokine profiling may help characterize neuroinflammatory disease mechanisms, although further validation of these findings in larger cohorts is needed.